Announcement Summary

Entity name

MAYNE PHARMA GROUP LIMITED

Date of this announcement

Tuesday September 13, 2022

The +securities the subject of this notification are:

☑ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
MYXAN	PERFORMANCE RIGHTS	852,515	13/09/2022

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

76115832963

1.3 ASX issuer code

MYX

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

13/9/2022

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☑ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ has an existing ASX security code ("existing class")

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class issued under an +employee incentive scheme

ASX +security code and description

MYXAN : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

13/9/2022

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

☑ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

☑ Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Aaron Gray	Aaron Gray	852,515

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

- Rights are being issued for nil consideration
- The rights will vest on 30 August 2023 subject to continued service
- There are no voting rights or rights to dividends whilst the participant holds the rights
- If vesting criteria are met, the rights will be automatically exercised at the date they vest and it is Company's intention to settle the rights with one fully paid ordinary share for each vested right with a portion of the shares sold to meet withholding tax obligations. The Company may also net settle with Mr Gray, so that the Company pays the relevant tax to the tax authorities and provides Mr Gray with the after-tax number of shares.

Any other information the entity wishes to provide about the +securities the subject of this notification

These rights are being issued to Mr Aaron Gray who joined Mayne Pharma in the role of Chief Financial Officer (CFO). Mr Gray has been granted a benefit in the form of cash and performance rights. This benefit is to compensate Mr Gray for the loss of a cash bonus he was eligible for at his prior employer.

Issue details

Number of +securities

852,515

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
MYX : ORDINARY FULLY PAID	1,739,815,508

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MYXAN : PERFORMANCE RIGHTS	60,150,833
MYXAT : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	16,706,827

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☑ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☑ No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☑ Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

852,515

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☑ No